Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats

FEBS Letters

Volumn 581, Issue 8, 2007, Pages 1631-1634

  Kume, Yukio ^a   Ikeda, Hitoshi ^a   Inoue, Morihiro ^a   Tejima, Kazuaki ^a   Tomiya, Tomoaki ^a   Nishikawa, Takako ^a   Watanabe, Naoko ^a   Ichikawa, Tatsuya ^a   Kaneko, Makoto ^a   Okubo, Shigeo ^a   Yokota, Hiromitsu ^a   Omata, Masao ^a   Fujiwara, Kenji ^b   Yatomi, Yutaka ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b YOKOHAMA ROSAI HOSPITAL   (Japan)

Author keywords

ADAMTS13; Dimethylnitrosamine; Hepatectomy; Hepatic stellate cell

Indexed keywords

CARBON TETRACHLORIDE; DIMETHYLNITROSAMINE; THIOACETAMIDE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CHEMISTRY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME REGULATION; LIVER CELL DAMAGE; LIVER RESECTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REDUCTION; STELLATE CELL;

ADAM PROTEINS; ANIMALS; APOPTOSIS; DIMETHYLNITROSAMINE; LIVER; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 34047201822     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2007.03.029     Document Type: Article

References (29)

1. Furlan M., Robles R., and Lamie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87 (1996) 4223-4234
2. Cohen H., Bull H.A., Seddon A., Enayat M.S., Hill F.G., Woolf N., and Machin S.J. Vascular endothelial cell function and ultrastructure in thrombotic microangiopathy following allogeneic bone marrow transplantation. Eur. J. Haematol. 43 (1989) 207-214
3. Furlan M., Robles R., Solenthaler M., Wassmer M., Sandoz P., and Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89 (1997) 3097-3103
4. Kinoshita S., et al. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int. J. Hematol. 74 (2001) 101-108
5. Sasahara Y., Kumaki S., Ohashi Y., Minegishi M., Kano H., Bessho F., and Tsuchiya S. Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome. Int. J. Hematol. 74 (2001) 109-114
6. Furlan M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339 (1998) 1578-1584
7. Zheng X., Chung D., Takayama T.K., Majerus E.M., Sadler J.E., and Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276 (2001) 41059-41063 [Epub 2001 Sep 13]
8. Soejima K., Mimura N., Hirashima M., Maeda H., Hamamoto T., Nakagaki T., and Nozaki C. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?. J. Biochem. (Tokyo) 130 (2001) 475-480
9. Cal S., Obaya A.J., Llamazares M., Garabaya C., Quesada V., and Lopez-Otin C. Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene 283 (2002) 49-62
10. Uemura M., et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106 (2005) 922-924
11. Zhou W., Inada M., Lee T.P., Benten D., Lyubsky S., Bouhassira E.E., Gupta S., and Tsai H.M. ADAMTS13 is expressed in hepatic stellate cells. Lab. Invest. 85 (2005) 780-788
12. Hirata K., Ogata I., Ohta Y., and Fujiwara K. Hepatic sinusoidal cell destruction in the development of intravascular coagulation in acute liver failure of rats. J. Pathol. 158 (1989) 157-165
13. Bruck R., Aeed H., Schey R., Matas Z., Reifen R., Zaiger G., Hochman A., and Avni Y. Pyrrolidine dithiocarbamate protects against thioacetamide-induced fulminant hepatic failure in rats. J. Hepatol. 36 (2002) 370-377
14. Kato S., Matsumoto M., Matsuyama T., Isonishi A., Hiura H., and Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion 46 (2006) 1444-1452
15. Higgins G., and Anderson R. Experimental pathology of the liver of the white rat following partial surgical removal. Arch. Pathol. 12 (1931) 186-202
16. Enzan H. Proliferation of Ito cells (fat-storing cells) in acute carbon tetrachloride liver injury. A light and electron microscopic autoradiographic study. Acta Pathol. Jpn. 35 (1985) 1301-1308
17. 4-treated mice.A light and electron microscopic autoradiographic study. Acta Pathol. Jpn. 37 (1987) 225-230
18. Enzan H., Himeno H., Iwamura S., Saibara T., Onishi S., Yamamoto Y., Miyazaki E., and Hara H. Sequential changes in human Ito cells and their relation to postnecrotic liver fibrosis in massive and submassive hepatic necrosis. Virchows Arch. 426 (1995) 95-101
19. Ledda-Columbano G.M., Coni P., Curto M., Giacomini L., Faa G., Oliverio S., Piacentini M., and Columbano A. Induction of two different modes of cell death, apoptosis and necrosis, in rat liver after a single dose of thioacetamide. Am. J. Pathol. 139 (1991) 1099-1109
20. Fujiwara K., et al. Intravascular coagulation in acute liver failure in rats and its treatment with antithrombin III. Gut 29 (1988) 1103-1108
21. Banno F., Kokame K., Okuda T., Honda S., Miyata S., Kato H., Tomiyama Y., and Miyata T. Complete deficiency in ADAMTS13 is prothrombotic, but it alone is not sufficient to cause thrombotic thrombocytopenic purpura. Blood 107 (2006) 3161-3166
22. Ko S., et al. Plasma ADAMTS13 activity may predict early adverse events in living donor liver transplantation: observations in 3 cases. Liver Transpl. 12 (2006) 859-869
23. Turner N., Nolasco L., Tao Z., Dong J.F., and Moake J. Human endothelial cells synthesize and release ADAMTS-13. J. Thromb. Haemost. 4 (2006) 1396-1404
24. Shang D., Zheng X.W., Niiya M., and Zheng X.L. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 108 (2006) 2207-2215 [Epub 2006 Apr 4]
25. Friedman S.L. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328 (1993) 1828-1835
26. Niiya M., Uemura M., Zheng X.W., Pollak E.S., Dockal M., Scheiflinger F., Wells R.G., and Zheng X.L. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4 (2006) 1063-1070
27. Mannucci P.M., Canciani M.T., Forza I., Lussana F., Lattuada A., and Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 98 (2001) 2730-2735
28. Lisman T., et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 44 (2006) 53-61
29. Yagita M., Uemura M., Nakamura T., Kunitomi A., Matsumoto M., and Fujimura Y. Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura. J. Hepatol. 42 (2005) 420-421